Emma M.
- Country
- Sweden
- Department
- Verksamhet Onkologi, Blå Stråket 2, 413 45 Göteborg
Research Overview
- Phase 1/2 Multicenter, Open-label, Randomized Study of Belzutifan and Palbociclib Versus Belzutifan Monotherapy in Advanced Renal Cell Carcinoma
- IZABRIGHT-BLADDER01: A Randomized, Open-label, Phase 2/3 trial of Izalontamab Brengitecan versus platinum-based chemotherapy for metastatic urothelial cancer in participants with disease progression on or after an immunotherapy-based treatment
Data & Insights
Has run more than one trial at 11 of 70 partner sites.
Specializations
Urologic Oncology
Specializes in investigating novel therapeutic approaches for advanced urological cancers, with particular focus on renal cell carcinoma and urothelial carcinoma.
- Advanced Clear Cell Renal Cell Carcinoma
- Muscle-Invasive Bladder Cancer
- Metastatic Urinary Tract Cancer
Explores targeted combination therapies and immunotherapy approaches in urologic malignancies.
Innovative Therapeutics
Investigates cutting-edge treatment combinations including targeted therapy and immunotherapy for urological cancers.
- Novel Drug Combinations
- Personalized Cancer Vaccines
- Immune Checkpoint Inhibition
Focuses on developing personalized treatment strategies for advanced urological malignancies.
Clinical Outcomes
Evaluates therapeutic efficacy through assessment of disease-free survival and objective response rates in urologic cancers.
- Treatment Response Assessment
- Safety Evaluation
- Disease Progression Monitoring
Specializes in determining optimal therapeutic approaches for high-risk urological cancers.
Related Investigators
Researchers in similar fields or departments
Want to know more about this investigator?
We can share extended profile information and contact details.
Is something out of date?
Tell us what needs correcting and we'll update this profile.